Abiopharma

🔍 Ehikian Stephen Bradley (Executive)

Company: C3.ai, Inc. (AI)

Report Date: 2026-03-30

Detailed Transactions and Holdings:

• Acquired 32,093 shares of Class A Common Stock (Direct)
  Date: 2026-03-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 773,679.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 52,194 shares of Class A Common Stock at $8.2211 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 721,485.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 47,316 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 674,169.00 | transaction_form_type: 4
• Acquired 47,316 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 229,804.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. The RSUs are fully vested.
• F2: Pursuant to the Issuer's policies and practice, these shares of Class A Common Stock were automatically withheld and sold by the Issuer to satisfy the Reporting Person's tax withholding obligations related to the vesting of RSUs previously granted and RSUs reported herein.
• F3: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.97 to $8.41, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F4: The shares are held by the Stephen Bradley Ehikian Revocable Trust, of which the Reporting Person is the sole trustee.